Sputum microRNA-screening reveals Prostaglandin EP3 receptor as selective target in allergen-specific immunotherapy,Clinical & Experimental Allergy

当前位置： X-MOL 学术 › Clin. Exp. Allergy › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Sputum microRNA-screening reveals Prostaglandin EP3 receptor as selective target in allergen-specific immunotherapy
Clinical & Experimental Allergy ( IF 6.1 ) Pub Date : 2021-09-12 , DOI: 10.1111/cea.14013
Constanze A Jakwerth ₁ , Adam M Chaker _{1,

2} , Ferdinand Guerth ₁ , Madlen Oelsner ₁ , Lisa Pechtold _{1,

2} , Lynn S Zur Bonsen _{1,

2} , Julia T Ullmann ₁ , Susanne Krauss-Etschmann _{3,

4} , Anna Erb ₁ , Josephine Kau _{1,

2} , Mirjam Plaschke _{1,

2} , Marlene Winkler _{1,

2} , Alexandra Kurz _{1,

2} , Antonia Kloss _{1,

2} , Julia Esser-von Bieren ₁ , Carsten B Schmidt-Weber ₁ , Ulrich M Zissler ₁

Affiliation

Several microRNAs (miRs) have been described as potential biomarkers in liquid biopsies and in the context of allergic asthma, while therapeutic effects on the airway expression of miRs remain elusive. In this study, we investigated epigenetic miR-associated mechanisms in the sputum of grass pollen-allergic patients with and without allergen-specific immunotherapy (AIT).

中文翻译：

痰 microRNA 筛查揭示前列腺素 EP3 受体是过敏原特异性免疫治疗的选择性靶标

几种 microRNAs (miRs) 已被描述为液体活检和过敏性哮喘背景下的潜在生物标志物，而对 miRs 气道表达的治疗效果仍然难以捉摸。在这项研究中，我们研究了有和没有过敏原特异性免疫疗法 (AIT) 的草花粉过敏患者痰中的表观遗传 miR 相关机制。

更新日期：2021-09-12

点击分享查看原文

点击收藏

阅读更多本刊最新论文

全部期刊列表>>